SaleJun 1, 2026, 08:57 AM
Edgewise Sells Sevasemten for Up to $2.65B; Focuses on Cardio
AI Summary
Edgewise Therapeutics announced an Asset Purchase Agreement to sell its sevasemten compound and neuromuscular program to Servier for up to $2.65 billion. The deal includes $1.55 billion in upfront cash and up to $1.1 billion in potential regulatory and commercial milestone payments. This transaction strengthens Edgewise's balance sheet, providing financial flexibility to advance its cardiovascular pipeline, and allows the company to become a cardiovascular-focused entity. The transaction is expected to close in Q3 2026.
Key Highlights
- Edgewise to sell its sevasemten neuromuscular program to Servier.
- Deal valued at up to $2.65 billion, including $1.55 billion upfront cash.
- Eligible for up to $1.1 billion in potential regulatory and commercial milestones.
- Milestones include $200 million for Becker MD US approval (adult/adolescent label).
- Milestones include $600 million for Duchenne MD US marketing approval.
- Milestones include $300 million for US net sales exceeding $550 million.
- Transaction expected to close in Q3 2026, subject to customary conditions.
- Edgewise will become a cardiovascular-focused company post-transaction.
Price Impact
More from EWTX